Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
CEA Is “Wrong Tool” That Doesn’t Fit into Japanese System: J&J Exec
The cost-effectiveness assessment (CEA) is the “wrong tool” in Japan’s drug pricing framework, and any expansion of the scheme could dial back all the progress recently made in the country to drive pharmaceutical innovation, warns a senior official of Johnson…
To read the full story
Related Article
BUSINESS
- Lilly Warns Against Off-Label Use of Mounjaro
June 11, 2026
- BMS Seeks Japan Approval for Mezigdomide in Multiple Myeloma
June 11, 2026
- SanBio Sees Akuugo Expanding to 20-30 Treatment Centers
June 11, 2026
- Rakuten Medical to Promote President Maeda to CEO
June 11, 2026
- Metagen Starts Global PI/II Trial of Oral FMT Therapy
June 11, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…